Wilex AG
Records under this name other than the patents Wilex AG holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 4 patents it holds.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 8,492,520 | Binding epitopes for G250 antibody Formerly held In force · From the USPTO record | In force | From the USPTO record | |
| US 7,691,375 | Adjuvant theraphy of G250-expressing tumors Term ended Term ended Apr 12, 2026 · From the USPTO record | Term ended | Term ended Apr 12, 2026 | From the USPTO record |
| US 7,884,206 | Method for producing 3-amidinophenylalanine derivatives Term ended Term ended Sep 13, 2025 · From the USPTO record | Term ended | Term ended Sep 13, 2025 | From the USPTO record |
| US 9,605,075 | Hybridoma cell line G250 and its use for producing monoclonal antibodies Term ended Term ended Mar 29, 2025 · From the USPTO record | Term ended | Term ended Mar 29, 2025 | From the USPTO record |
| US 7,608,623 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors Term ended Term ended Nov 16, 2024 · From the USPTO record | Term ended | Term ended Nov 16, 2024 | From the USPTO record |
| US 8,828,381 | Co-administration of CG250 and IL-2 or IFN-alpha for treating cancer such as renal cell carcinomas Term ended Term ended Jun 4, 2024 · From the USPTO record | Term ended | Term ended Jun 4, 2024 | From the USPTO record |
| US 7,807,681 | Hydroxyamidine and hydroxyguanidine compounds as urokinase inhibitors Term ended Term ended May 26, 2024 · From the USPTO record | Term ended | Term ended May 26, 2024 | From the USPTO record |
| US 7,659,396 | Method for the production of phenylalanine derivatives Term ended Term ended Apr 23, 2024 · From the USPTO record | Term ended | Term ended Apr 23, 2024 | From the USPTO record |
| US 7,247,724 | Method for the production of phenylalanine derivatives Term ended Term ended Dec 15, 2023 · From the USPTO record | Term ended | Term ended Dec 15, 2023 | From the USPTO record |
| US 7,632,496 | Co-administration of cG250 and IL-2 or IFN-α for treating cancer such as renal cell carcinomas Formerly held Term ended Term ended Jul 14, 2023 · From the USPTO record | Term ended | Term ended Jul 14, 2023 | From the USPTO record |